News
FDA to Ask Sarepta to Halt Elevidys Shipments
Digest more
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...
The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...
The drop comes the day after the drugmaker said it would add a so-called black-box warning to its gene therapy Elevidys after ...
Shares of Sarepta Therapeutics plummeted nearly 30% premarket Friday following a report that a third patient has died during ...
As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Sarepta Therapeutics stock soared over 30% after the pharmaceutical company said it would lay off about 500 employees. It ...
Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback